Современный подход к этиологии, патогенезу, лечению и профилактике бактериального вагиноза и вагинального кандидоза
Современный подход к этиологии, патогенезу, лечению и профилактике бактериального вагиноза и вагинального кандидоза
Пустотина О.А. Современный подход к этиологии, патогенезу, лечению и профилактике бактериального вагиноза
и вагинального кандидоза. Гинекология. 2015; 17 (3): 79–82.
________________________________________________
Pustotina O.A. The modern approach to the etiology, pathogenesis, treatment and prevention of bacterial vaginosis and vaginal candidiasis. Gynecology. 2015; 17 (3): 79–82.
Современный подход к этиологии, патогенезу, лечению и профилактике бактериального вагиноза и вагинального кандидоза
Пустотина О.А. Современный подход к этиологии, патогенезу, лечению и профилактике бактериального вагиноза
и вагинального кандидоза. Гинекология. 2015; 17 (3): 79–82.
________________________________________________
Pustotina O.A. The modern approach to the etiology, pathogenesis, treatment and prevention of bacterial vaginosis and vaginal candidiasis. Gynecology. 2015; 17 (3): 79–82.
В статье с современных позиций рассматриваются этиология, патогенез, диагностика, лечение и профилактика бактериального вагиноза и вагинального кандидоза – самых частых причин вагинальных выделений. Оцениваются место комбинированных препаратов
и значение комплексного подхода в лечении и профилактике нарушений вагинального микробиоценоза. Ключевые слова: бактериальный вагиноз, вагинальный кандидоз.
________________________________________________
The article outlines modern points of etiology, pathogenesis, diagnosis, treatment and prevention of bacterial vaginosis and vaginal candidiasis – the most common causes of vaginal discharge. Place of the combined drugs and the importance of an integrated campaign in the treatment and prevention of vaginal disorders microbiocenosis are also discussed. Key words: bacterial vaginosis, vaginal candidiasis.
1. Filler SG. Insights from human studies into the host defense against candidiasis. Cytokine 2012; 58 (1): 129–32.
2. Шейка матки, влагалище, вульва. Физиология, патология, кольпоскопия, эстетическая коррекция. Руководство для практикующих врачей. Под ред. С.И.Роговской, Е.В.Липовой. М.: StatusPraesens, 2014. / Sheika matki, vlagalishche, vul'va. Fiziologiia, patologiia, kol'poskopiia, esteticheskaia korrektsiia: rukovodstvo dlia praktikuiushchikh vrachei. Pod red. S.I.Rogovskoi, E.V.Lipovoi. M.: StatusPraesens, 2014. [in Russian]
3. Sweet RL, Gibbs RS. Infectious diseases of the female genital tract. 5th ed. Lippincott Williams Wilkins, 2009.
4. Гуртовой Б.Л., Кулаков В.И., Воропаева С.Д. Применение антибиотиков в акушерстве и гинекологии. М.: Триада-Х, 2004. / Gurtovoi B.L., Kulakov V.I., Voropaeva S.D. Primenenie antibiotikov v akusherstve i ginekologii. M.: Triada-Kh, 2004. [in Russian]
5. Dols JA, Smit PW, Kort R et al. Microarray-based identification of clinically relevant vaginal bacteria in relation to bacterial vaginosis. Am J Obstet Gynecol 2011; 204: 305.e1–7.
6. Hickley RJ, Zhou X, Pierson JD et al. Understanding vaginal microbiome completely from an ecological perspective. Transl Res 2012; 160: 267–82.
7. Ravel J, Gajer P, Abdo Z et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA 2011; 108: 4680–7.
8. Swidsinski A, Dorffel Y, Loening-Baucke V et al. Gardnerella biofilm involves females and males and is sexually transmitted. Gynecol Obstet Invest 2010; 70: 256–63.
9. Donders GG, Zodzika J, Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Exp Opin Pharmacother 2014; 15 (5): 645–57.
10. Desseauve D, Chantrel J, Fruchart A et al. Prevalence and risk factors of bacterial vaginosis during the first trimester of pregnancy in a large French population-based study. Eur J Obstet Gynecol Reprod Biol 2012; 163: 30–4.
11. Bothuyne-Queste E et al. Is the bacterial vaginosis risk factor of prematurity? Study of a cohort of 1336 patients in the hospital of Arras. J Gynecol Obstet Biol Reprod 2012; 41 (3): 262–70.
12. Mittal V, Jain A, Pradeep Y. Development of modified diagnostic criteria for bacterial vaginosis at peripheral health centres in developing countries. J Infect Dev Ctries 2012; 6 (5): 373–7.
13. CDC. Sexually Transmitted Diseases Treatment Guidelines 2010. http://www.cdc.gov/std/treatment/2010/pid.htm
14. Sherrard J, Donders G, White D. European (IUSTI/WHO) Guideline on the management of vaginal discharge in women reproductive age. 2011.
15. Клинические рекомендации РОАГ. Акушерство и гинекология. 4-е изд. Под ред. В.Н.Серова, Г.Т.Сухих. М.: ГЭОТАР-Медиа, 2014. / Klinicheskie rekomendatsii ROAG. Akusherstvo i ginekologiia. 4-e izd. Pod red. V.N.Serova, G.T.Sukhikh. M.: GEOTAR-Media, 2014. [in Russian]
16. Подзолкова Н.М., Никитина Т.И. Сравнительная оценка различных схем лечения больных с бактериальным вагинозом и неспецифическим вульвовагинитом. Рос. вестн. акушера-гинеколога. 2012; 4: 75–81. / Podzolkova N.M., Nikitina T.I. Sravnitel'naia otsenka razlichnykh skhem lecheniia bol'nykh s bakterial'nym vaginozom i nespetsificheskim vul'vovaginitom. Ros. vestn. akushera-ginekologa. 2012; 4: 75–81. [in Russian]
17. Verstraelen H, Verhelst R. Bacterial vaginosis: an update on diagnosis and treatment. Expert Rev Anti Infect Ther 2009; 7: 1109–24.
18. Swidsinski A, Verstraelen H, Loening-Baucke V et al. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One 2013; 8: e53997.
19. Подзолкова Н.М., Никитина Т.И. Новые возможности терапии рецидивирующих вульвовагинальных инфекций: анализ и обсуждение результатов многоцентрового исследования БИОС-2. Акушерство и гинекология. 2014; 4: 68–74. / Podzolkova N.M., Nikitina T.I. Novye vozmozhnosti terapii retsidiviruiushchikh vul'vovaginal'nykh infektsii: analiz i obsuzhdenie rezul'tatov mnogotsentrovogo issledovaniia BIOS-2. Akusherstvo i ginekologiia. 2014; 4: 68–74. [in Russian]
20. Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double blind, randomized, placebo-controlled study. Am J Obstet Gynecol 2010; 203: 1200–8.
21. Zodzika J, Rezerberga D, Donders G et al. Impact of vaginal ascorbic acid on abnormal vaginal microflora. Arch Gynecol Obstet 2013; 288: 1039–44.
22. Гомберг М.А., Плахова К. Терапия трихомониаза и бактериального вагиноза: проблемы и пути решения. Consilium Medicum. 2005; 7 (3): 210–4. / Gomberg M.A., Plakhova K. Terapiia trikhomoniaza i bakterial'nogo vaginoza: problemy i puti resheniia. Consilium Medicum. 2005; 7 (3): 210–4. [in Russian]
23. Ozyurt E. Efficacy of 7-day treatment with metronidazole plus miconazole (Neo-Penotran®) – a triple-active pessary for the treatment of single and mixed vaginal infections. Inter J Gynecol Obstet 2001; 74 (1): 35–43.
24. Peixoto F, Camargos A, Duarte G et al. Efficacy and tolerance of metronidazole and miconazole nitrate in treatment of vaginitis. Intern J Gynecol Obstet 2008; 102: 287–92.
25. Schwebke JR, Lensing SY, Sobel J.I ntravaginal Metronidazole/Miconazole for the treatment of Vaginal Trihomoniasis. Sex Transmit Dis 2013; 40 (9): 679–760.
26. Инструкция к препарату Гайномакс. http://www.vidal.ru/drugs/gynomax__30899 / Instuktsiia k preparatu Gainomaks. http://www.vidal.ru/drugs/gynomax__30899 [in Russian]
27. Cagayan S, Bravo SL, Fallarme A. Randomized, singleblind, one centre trial comparing the efficacy, safety and acceptability of 3 day versus 7 day treatment of Gynomax in vaginitis treatment. Controversies in obstetrics, gynecology and infertility. China 2009, Nov 12–15.
28. Фофанова И.Ю., Прилепская В.Н. Рациональные подходы к терапии бактериального вагиноза. Гинекология. 2013; 15 (5)/ Fofanova I.Iu., Prilepskaia V.N. Ratsional'nye podkhody k terapii bakterial'nogo vaginoza. Gynekology. 2013; 15 (5). [in Russian]
29. Pustotina OA. Urogenital infection in pregnant women: clinical signs and outcome. J Perinat Med 2013; 41: 135.
30. Brocklehurst P, Gordon A, Heatly E et al. Antibiotics for treating bacterial vaginosis in pregnancy. Cochr Database Syst Rev 2013; 1: CD000262.
31. Weissenbacher ER, Donders G, Unzeitig V et al. Fluomizin Study Group. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest 2012; 73: 8–15.
________________________________________________
1. Filler SG. Insights from human studies into the host defense against candidiasis. Cytokine 2012; 58 (1): 129–32.
2. Sheika matki, vlagalishche, vul'va. Fiziologiia, patologiia, kol'poskopiia, esteticheskaia korrektsiia: rukovodstvo dlia praktikuiushchikh vrachei. Pod red. S.I.Rogovskoi, E.V.Lipovoi. M.: StatusPraesens, 2014. [in Russian]
3. Sweet RL, Gibbs RS. Infectious diseases of the female genital tract. 5th ed. Lippincott Williams Wilkins, 2009.
4. Gurtovoi B.L., Kulakov V.I., Voropaeva S.D. Primenenie antibiotikov v akusherstve i ginekologii. M.: Triada-Kh, 2004. [in Russian]
5. Dols JA, Smit PW, Kort R et al. Microarray-based identification of clinically relevant vaginal bacteria in relation to bacterial vaginosis. Am J Obstet Gynecol 2011; 204: 305.e1–7.
6. Hickley RJ, Zhou X, Pierson JD et al. Understanding vaginal microbiome completely from an ecological perspective. Transl Res 2012; 160: 267–82.
7. Ravel J, Gajer P, Abdo Z et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA 2011; 108: 4680–7.
8. Swidsinski A, Dorffel Y, Loening-Baucke V et al. Gardnerella biofilm involves females and males and is sexually transmitted. Gynecol Obstet Invest 2010; 70: 256–63.
9. Donders GG, Zodzika J, Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Exp Opin Pharmacother 2014; 15 (5): 645–57.
10. Desseauve D, Chantrel J, Fruchart A et al. Prevalence and risk factors of bacterial vaginosis during the first trimester of pregnancy in a large French population-based study. Eur J Obstet Gynecol Reprod Biol 2012; 163: 30–4.
11. Bothuyne-Queste E et al. Is the bacterial vaginosis risk factor of prematurity? Study of a cohort of 1336 patients in the hospital of Arras. J Gynecol Obstet Biol Reprod 2012; 41 (3): 262–70.
12. Mittal V, Jain A, Pradeep Y. Development of modified diagnostic criteria for bacterial vaginosis at peripheral health centres in developing countries. J Infect Dev Ctries 2012; 6 (5): 373–7.
13. CDC. Sexually Transmitted Diseases Treatment Guidelines 2010. http://www.cdc.gov/std/treatment/2010/pid.htm
14. Sherrard J, Donders G, White D. European (IUSTI/WHO) Guideline on the management of vaginal discharge in women reproductive age. 2011.
15. Klinicheskie rekomendatsii ROAG. Akusherstvo i ginekologiia. 4-e izd. Pod red. V.N.Serova, G.T.Sukhikh. M.: GEOTAR-Media, 2014. [in Russian]
16. Podzolkova N.M., Nikitina T.I. Sravnitel'naia otsenka razlichnykh skhem lecheniia bol'nykh s bakterial'nym vaginozom i nespetsificheskim vul'vovaginitom. Ros. vestn. akushera-ginekologa. 2012; 4: 75–81. [in Russian]
17. Verstraelen H, Verhelst R. Bacterial vaginosis: an update on diagnosis and treatment. Expert Rev Anti Infect Ther 2009; 7: 1109–24.
18. Swidsinski A, Verstraelen H, Loening-Baucke V et al. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One 2013; 8: e53997.
19. Podzolkova N.M., Nikitina T.I. Novye vozmozhnosti terapii retsidiviruiushchikh vul'vovaginal'nykh infektsii: analiz i obsuzhdenie rezul'tatov mnogotsentrovogo issledovaniia BIOS-2. Akusherstvo i ginekologiia. 2014; 4: 68–74. [in Russian]
20. Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double blind, randomized, placebo-controlled study. Am J Obstet Gynecol 2010; 203: 1200–8.
21. Zodzika J, Rezerberga D, Donders G et al. Impact of vaginal ascorbic acid on abnormal vaginal microflora. Arch Gynecol Obstet 2013; 288: 1039–44.
22. Gomberg M.A., Plakhova K. Terapiia trikhomoniaza i bakterial'nogo vaginoza: problemy i puti resheniia. Consilium Medicum. 2005; 7 (3): 210–4. [in Russian]
23. Ozyurt E. Efficacy of 7-day treatment with metronidazole plus miconazole (Neo-Penotran®) – a triple-active pessary for the treatment of single and mixed vaginal infections. Inter J Gynecol Obstet 2001; 74 (1): 35–43.
24. Peixoto F, Camargos A, Duarte G et al. Efficacy and tolerance of metronidazole and miconazole nitrate in treatment of vaginitis. Intern J Gynecol Obstet 2008; 102: 287–92.
25. Schwebke JR, Lensing SY, Sobel J.I ntravaginal Metronidazole/Miconazole for the treatment of Vaginal Trihomoniasis. Sex Transmit Dis 2013; 40 (9): 679–760.
26. Инструкция к препарату Гайномакс. http://www.vidal.ru/drugs/gynomax__30899 / Instuktsiia k preparatu Gainomaks. http://www.vidal.ru/drugs/gynomax__30899 [in Russian]
27. Cagayan S, Bravo SL, Fallarme A. Randomized, singleblind, one centre trial comparing the efficacy, safety and acceptability of 3 day versus
7 day treatment of Gynomax in vaginitis treatment. Controversies in obstetrics, gynecology and infertility. China 2009, Nov 12–15.
28. Fofanova I.Iu., Prilepskaia V.N. Ratsional'nye podkhody k terapii bakterial'nogo vaginoza. Gynekology. 2013; 15 (5). [in Russian]
29. Pustotina OA. Urogenital infection in pregnant women: clinical signs and outcome. J Perinat Med 2013; 41: 135.
30. Brocklehurst P, Gordon A, Heatly E et al. Antibiotics for treating bacterial vaginosis in pregnancy. Cochr Database Syst Rev 2013; 1: CD000262.
31. Weissenbacher ER, Donders G, Unzeitig V et al. Fluomizin Study Group. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest 2012; 73: 8–15.
Авторы
О.А.Пустотина*
ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6
*rudn@rudn.ru
________________________________________________
O.A.Pustotina*
People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6
*rudn@rudn.ru